Data sourced from FasterCures, a center of the Milken Institute.
Interactive visualization by FirstPerson, a design & storytelling company.
Covid-19 Vaccine Tracker
Rapidly evolving, check back often.
Last updated:
July 10, 2020 10:16 PM
PST
192
vaccines are in development.
16
are now in clinical testing.
The race to develop, approve, and manufacture a COVID-19 vaccine is fluid—and urgent.
How long will it take? Some say not long.
Let's put that into perspective.
Scroll
Leading Candidates
Farthest Along*
Clinical Phase
Univ. of Oxford/AstraZeneca
II/III
Wuhan Inst./Sinopharm
II
CanSino Biologics
II
Moderna
II
Inst. of Medical Biology
II
Sinovac/Instituto Butantan
II
Beijing Inst./Sinopharm
II
BioNTech/Fosun/Pfizer
I/II
Imperial College London
I/II
Novavax
I/II
*Ranked by entry into latest phase of development. Clinical phases move when it is publicly reported that the product has been dosed in a trial.
View data for vaccines and treatments.
How to read this Graphic
There are currently
These fall into
At this time,
But not all vaccines are created equal.
192
vaccines in development 
for COVID-19.
This syringe represents vaccines currently in development. Each row is an individual vaccine.
Inactivated Virus
Live Attenuated Virus
Protein Subunit
DNA-Based
RNA-Based
replicating viral vector
Non-Replicating VIral Vector
Virus-Like Particle
Other Vaccines
Vaccine Categories
How many are out of the pre-clinical phase?
9
different product categories / platforms.
More about the timeline, phases, manufacturing, and approaches to develop a COVID-19 vaccine.
Clinical trial phases read in columns from left to right on the syringe.

vaccines still in the pre-clinical phase remain transparent.
16
vaccines are in one of four phases of clinical testing.
I
II
III
RR
Timeline
The vaccine development process typically takes a decade, but COVID-19 timelines are being compressed due to the global urgency of the pandemic.
Typical Vaccine Development
Possible COVID-19 vaccine development
12-18 MOnths
~10 Years
Some suggest a timeline from start of development to public use is 12-18 months from January 2020, when the genetic sequence of the virus that causes COVID-19 was published.
How Vaccines Work
Weak Germs Injected
Traditionally, vaccines contain the same germs, either killed or weakened, or part of the germ that causes the disease.
Antibodies Created
They stimulate your immune system to produce antibodies, as if you were exposed to the germ.
Immunity Developed
After getting vaccinated, one develops immunity to that disease without having to get it first.
Vaccines don’t cure diseases.
They prevent them.
stages of development
After pre-clinical studies are completed, the multiple phases of the clinical trial process test whether new vaccines are safe and effective before going public—culminating in a regulatory review. Phase IV is post-approval and monitors real-world effectiveness.
This process usually takes approximately 10 years, but governments and industry are fast-tracking these vaccines while maintaining safety and efficacy standards.
PRE
Pre-Clinical Phase
  • Collects data to support feasibility and safety
  • Involves iterative non-human testing
  • Evaluates toxic and pharmacological effects
  • Normally occurs before human testing can begin
I
Clinical phase
  • Small study of healthy people
  • Evaluates safety and immune response at different doses
  • Typically takes 1-2 years, but for COVID-19 trials, expected to take 3 months
II
Clinical phase
  • Studies 100s of people
  • Further evaluates safety, assesses efficacy, and informs optimal dose and vaccine schedule
  • Typically takes 2-3 years, but for COVID-19 trials, expected to take 8 months
III
Clinical phase
  • Studies 1000s of people
  • Further evaluates safety and efficacy
  • Typically takes 2-4 years, but for COVID-19 trials, may be combined with Phase II
RR
Regulatory Review
  • Government agency reviews trial data and licensing application information before approval
  • Can happen while manufacturing has started
  • Typically takes 1-2 years, but for COVID-19, expedited to take a few months
IV
Clinical Phase
  • Post-approval studies that monitor effectiveness in real-world conditions
  • Testing begins after vaccine has been released to public
Once a vaccine is approved, do we get it right away?
Early Manufacturing
Oftentimes developers will try to ensure that enough of a vaccine is ready to ship the moment approval comes in by beginning the manufacturing process during clinical trials.
But a manufacturer loses significant resources if approval doesn’t come or a vaccine is no longer needed in the marketplace. The more vaccines produced, the more risk incurred. To mitigate risk and encourage manufacturing, governments, industry and international organizations are working together.
Pre
I
II
III
RR
IV
NON-IDEAL CASE
Developer manufactures mass quantities of a vaccine, but does not get approval, leaving the public without a vaccine and resources put into manufacturing lost. For COVID-19 vaccine development, private philanthropy has pledged to pay the lost costs for this scenario.
Pre
I
II
III
RR
IV
GOOD CASE
Developer gets fast approval, but has not manufactured enough of a vaccine to distribute in mass quantities. The public must wait longer for more vaccines to become available.
Pre
I
II
III
RR
IV
BEST CASE
Developer gets fast approval and has been concurrently manufacturing the vaccine during clinical trials.
The vaccine is now ready to distribute in mass quantities.
A race ARound the world
To expedite development and distribution of a vaccine, unprecedented international alliances have been formed and billions have been allocated. But simultaneous initial development will eventually give way, and only a select few of the most promising candidates will receive funding towards eventual licensing and distribution.
That is why many different types of vaccines are being researched and tested—some traditional, others experimental. Each product category has its own advantages and disadvantages, and we will likely need more than one vaccine to protect all people around the globe.
Meet the candidates.
Inactivated virus
These consist of viruses grown in culture and then killed as a means to reduce virulence (ability to infect and cause harm) and thus prevent infection from the vaccine. One benefit is they can be given to people with weakened immune systems. Examples include polio and influenza vaccines.
Sinovac/ Instituto Butantan
Inactivated (inactivated + alum); CoronaVac (formerly PiCoVacc)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for SARS
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III enrolling in Brazil in July 2020; Phase II started in June 2020; preliminary results from Phase I/II trials released June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04456595, NCT04352608, NCT04383574
Institute of Medical Biology, Chinese Academy of Medical Sciences
Inactivated
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase II began June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04412538
Wuhan Institute of Biological Products/ Sinopharm
Inactivated
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Early Phase I/II trial results released June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000031809
Beijing Institute of Biological Products/ Sinopharm
Inactivated
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
In Phase II, June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000032459
Selcuk University
Inactivated
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
KM Biologics
Inactivated (inactivated + alum)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for JE, Zika
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Valneva/ Dynavax
Inactivated (Inactivated + CpG 1018), VLA2001
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Japanese Encephalitis
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
National Research Centre, Egypt
Inactivated whole virus
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Sinovac/ Dynavax
Inactivated (inactivated + CpG 1018)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Osaka University / BIKEN / NIBIOHN
Inactivated
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Research Institute for Biological Safety Problems, Republic of Kazakhstan
Inactivated
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Beijing Minhai Biotechnology Co., Ltd.
Inactivated
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher

Product Description
PRE
I
II
III
RR
IV
Live attenuated virus
In contrast to inactivated virus vaccines, these vaccines, also whole viruses, are live to elicit a stronger immune response but weakened to reduce virulence. Examples include those for measles, mumps, and tuberculosis.
Mehmet Ali Aydinlar University/ Acıbadem Labmed Health Services A.S.
Codon deoptimized live attenuated vaccines
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Meissa Vaccines 
MV-014-210
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for RSV
Anticipated Next Steps
Anticipated Next Steps
n/a
Start Phase 1 beginning of 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Indian Immunologicals Ltd/ Griffith University
Codon deoptimized live attenuated virus
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Codagenix / Serum Institute of India
Codon deoptimized live attenuated virus
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for HAV, InfA, ZIKV, FMD, SIV, RSV, DENV
Anticipated Next Steps
Anticipated Next Steps
n/a
Animal data in summer 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PRE
I
II
III
RR
IV
Protein subunit
Rather than introducing whole viruses to an immune system, a fragment of the virus is used to trigger an immune response and stimulate immunity. Examples include the subunit vaccines against Hepatitis B and shingles.
Vaxine Pty Ltd/ Flinders University/ Oracle/ Medytox/ Sypharma
Protein subunit; recombinant spike protein with Advax adjuvant (COVAX-19)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I trial started July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04453852
Clover Biopharmaceuticals Inc./ GSK/ Dynavax
Protein subunit, native like trimeric subunit spike protein
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)
Related use
Related use
n/a
Same platform as vaccine candidates for HIV, RSV, Influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I trial started June 2020, preliminary results expected August 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04405908
Novavax/ Emergent BioSolutions/ Praha Vaccines/Serum Institute of India/ AGC Biologics
Protein subunit; Full-length recombinant SARS COV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M (NVX-CoV2373)
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)/ US Department of Defense
Related use
Related use
n/a
Same platform as vaccine candidates for RSV, CCHF, HPV, VZV, EBOV
Anticipated Next Steps
Anticipated Next Steps
n/a
Will join US Operation Warp Speed vaccine trials, Phase III trial to start in fall 2020; Phase I/II started May 2020; top-line data expected July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04368988
InnoMedica
Protein subunit, TaliCoVax19
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Bogazici University
Peptide + novel adjuvant
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Izmir Biomedicine and Genome Center
Recombinant S protein
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Virginia
S subunit intranasal liposomal formulation with GLA/3M052 adjs.
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ImmunoPrecise/ LiteVax BV
Spike-based (epitope screening)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese Academy of Sciences
Adjuvanted recombinant protein (RBD-Dimer)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Received approval to launch clinical trials in China in June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04445194
National Research Centre, Egypt
Protein Subunit S, N, M & S1 protein
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Helix Biogen Consult, Ogbomoso & Trinity Immonoefficient Laboratory, Ogbomoso, Oyo State, Nigeria
Subunit
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Baiya Phytopharm/ Chula Vaccine Research Center
Plant-based subunit (RBD-Fc + Adjuvant)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IMV, Inc., Canadian Center for Vaccinology at Dalhousie University, Izaak Walton Killam Health Center, Nova Scotia Health Authority, Canadian Immunization Research Network, University of Laval, Global Urgent and Advanced Research and Development in Canada
Protein subunit; DPX-COVID-19, protein subunit, peptide antigens formulated in LNP
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for cancer and infectious diseases, including malaria and anthrax
Anticipated Next Steps
Anticipated Next Steps
n/a
Start Phase I testing by summer 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Intravacc/Epivax

Outer Membrane Vesicle (OMV)-subunit x

Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of San Martin and CONICET, Argentina
Protein subunit
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Yisheng Biopharma
Protein subunit, recombinant protein
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
WRAIR / USAMRIID
Protein subunit; S protein
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Verndari/ University of California, Davis
Spike protein; VaxiPatch microneedle array dermal patch
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccines against influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start summer 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Vabiotech
Protein subunit, recombinant S protein in IC-BEVS
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Vaxil Bio
Protein subunit; peptide
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Queensland / GSK / Dynavax/ CSL
Protein subunit; molecular clamp stabilized Spike protein
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)/Queensland Government/Federal Government (Australia)/Paul Ramsay Foundation
Related use
Related use
n/a
Same platform as vaccine candidates for Nipah, influenza, Ebola, Lassa
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Alberta
Protein subunit; spike based
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Hepatitis C
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of California, San Diego
Protein subunit; plant virus nanotechnology formulated as injectable and microneedle patch
Funder
Funder
n/a
National Science Foundation (Rapid Response Research [RAPID] grant)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
St. Petersburg Scientific Research Institute of Vaccines and Serums
Protein subunit, recombinant protein, nanoparticles (based on S-protein and other epitopes)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Quadram Institute Biosciences
OMV-based vaccine
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Flu A, plaque
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
MOGAM Institute for Biomedical Research, GC Pharma
Protein subunit
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
LakePharma, Inc.
Protein subunit, nanoparticle vaccine
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Lomonosov Moscow State University
Structurally modified spherical particles of the tobacco mosaic virus (TMV)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Neovii/Tel Aviv University
RBD-based
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Medigen Vaccine Biologics Corp/ NIAID/ Dynavax
S-2 P protein + CpG 1018
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
National Institute of Infectious Disease, Japan
Protein subunit, S protein + adjuvant
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Osaka University / BIKEN / National Institutes of Biomedical Innovation, Japan
Protein subunit, VLP-recombinant protein + adjuvant
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Kentucky BioProcessing (British American Tobacco)
RBD-based
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
OncoGen
Protein subunit, synthetic long peptide vaccine candidate for S and M proteins
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
MIGAL Galilee Research Institute
Protein subunit; oral E. coli-based protein expression system of S and N proteins
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
PDS Biotechnology
PDS-0203; Versamune T-cell activating technology
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccines against cancers, HBV, influenza, and tuberculosis
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Max-Planck Institute of Colloids and Interfaces
Targeted (Langerhans cell specific) protein subunit; spike based
Funder
Funder
n/a
KHAN-1 Technology Transfer Fund I GmbH & Co KG
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Intravacc/Epivax
Outer Membrane Vesicle (OMV)-peptide
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Innovax / Xiamen University / GSK
Protein subunit; COVID-19 XWG-03 truncated Spike proteins
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for HPV
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
iBio / CC-Pharming
Protein subunit; Subunit protein, plant produced
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Heat Biologics (Zolovax)/ University of Miami/ Waisman Biomanufacturing
Protein subunit (gp-96 backbone)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for cancer (NSCLC), HIV, malaria, Zika
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
Protein subunit; subunit vaccine
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ExpreS2ion
Protein subunit, drosophila S2 insect cell expression system VLPs
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
Protein subunit; peptide vaccine
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Ebola
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Generex / EpiVax
Protein subunit; Ii-Key peptide
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for HIV, SARS-CoV, Influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Flow Pharma
Protein subunit, peptide
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Ebola, Marburg, HIV, Zika, Influenza, HPV therapeutic vaccine, Breast Cancer
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EpiVax / University of Georgia
Protein subunit; S protein
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Inf H7N9
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EpiVax
Protein subunit EPV-CoV-19
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
AnyGo Technology
Protein subunit, recombinant S1-Fc fusion protein
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
BiOMVis Srl/ University of Trento
OMV-based vaccine
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Baylor College of Medicine
Protein subunit; S1 or RBD protein
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for SARS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Biological E Ltd
Protein subunit; adjuvanted protein subunit (RBD)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Applied Biotechnology Institute, Inc.
Orally delivered, heat stable subunit
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Axon Neuroscience SE
Peptides derived from Spike protein
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Chulalongkorn University/ GPO, Thailand
RBD protein fused with Fc of IgG + Adjuvant
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
AJ Vaccines
Protein subunit; S protein
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Pittsburgh
PittCoVacc, Protein subunit, microneedle arrays S1 subunit
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start as early as June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Cambridge / DIOSynVax
Protein subunit; S protein
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Influenza, Ebola
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start as early as June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Sanofi Pasteur / GSK
Protein subunit; S protein, baculovirus production
Funder
Funder
n/a
Biomedical Advanced Research and Development Authority (BARDA)
Related use
Related use
n/a
Same platform as vaccine candidates for Influenza, SARS-CoV (FDA approved vaccine)
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II to start in September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
VIDO-InterVac, University of Saskatchewan
Protein subunit, adjuvanted microsphere peptide
Funder
Funder
n/a
The Government of Saskatchewan and the Canadian Federal Government
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Animal testing results expected in April 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
PREVENT-nCoV consortium (AdaptVac, Institute for Tropical Medicine at University of Tubingen, Leiden University Medical Center, University of Copenhagen, ExpreS2ion Biotechnologies, Wageningen University)/ Bavarian Nordic
Protein subunit, capsid-like particle (CLP)
Funder
Funder
n/a
European Commission (Horizon 2020 Program)
Related use
Related use
n/a
Same platform as vaccine candidates for HPV
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to begin by February 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
UMN Pharma (Shionogi)
Protein subunit; recombinant protein vaccine, utilizing baculovirus expression vector system technology
Funder
Funder
n/a
Japan Agency for Medical Research and Development
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start by end of 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PRE
I
II
III
RR
IV
DNA-Based
These next-gen vaccines work through introducing viral genetic material (DNA) that cells use to make viral proteins that induce a range of immune response types. They can potentially be developed more quickly and easily than other vaccines, but no DNA vaccines have been approved for human use.
Inovio Pharmaceuticals/Beijing Advaccine Biotechnology/VGXI Inc./ Richter-Helm BioLogics/Ology Bioservices
DNA plasmid vaccine with electroporation; INO-4800
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI) / Gates Foundation / US Department of Defense
Related use
Related use
n/a
Same platform as multiple vaccine candidates
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I initial data released June 30, 2020; Phase II/III trials start July/August 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04336410, NCT04447781
Genexine Consortium (GenNBio, International Vaccine Institute, Korea Advanced Institute of Science and Technology (KAIST), Pohang University of Science and Technology (POSTECH)/ Binex
DNA vaccine (GX-19)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start in July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04445389
Ege University
DNA
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Osaka University/ AnGes/ Takara Bio/ Cytiva
DNA plasmid
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start in July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
JapicCTI-205328
Scancell/ University of Nottingham/ Nottingham Trent University
DNA plasmid vaccine RBD&N
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for cancer
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start in Q1 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Mediphage Bioceuticals/ University of Waterloo
msDNA vaccine
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Zydus Cadila Healthcare Limited
DNA plasmid
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II to start in July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CTRI/2020/07/026352
Entos Pharmaceuticals/ Cytiva
DNA; Covigenix
Funder
Funder
n/a
Canadian Institutes of Health Research (CIHR)/ Research Nova Scotia (RNS)/ Institute for Ageing (IA)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II to start in late July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
National Research Centre, Egypt
DNA plasmid vaccine S, S1, S2, RBD & N
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Chula Vaccine Research Center
DNA with electroporation
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Takis/ Applied DNA Sciences/ Evvivax
DNA
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Animal results released in May 2020; Phase I to start in fall 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Symvivo
bacTRL-Spike
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Immunomic Therapeutics / EpiVax / PharmaJet
DNA plasmid, needle-free delivery
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for SARS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
BioNet Asia
DNA
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
OPENCORONA - Cobra Biologics / Karolinska Institute
DNA with electroporation
Funder
Funder
n/a
European Commission (Horizon 2020 Program)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start in 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PRE
I
II
III
RR
IV
RNA-based
Similar to DNA vaccines, these experimental vaccines provide immunity through introduction of genetic material (RNA). RNA vaccines can also be potentially developed more quickly and easily than other vaccines. No RNA vaccines have been approved for human use.
Moderna/ NIAID/ Lonza/ Catalent/ Rovi
RNA; LNP-encapsulated mRNA (mRNA 1273)
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)/ Biomedical Advanced Research and Development Authority (BARDA)
Related use
Related use
n/a
Same platform as vaccine candidates for multiple candidates
Anticipated Next Steps
Anticipated Next Steps
n/a
Will join US Operation Warp Speed vaccine Phase III trials in July 2020; Completed enrollment for both cohorts of the Phase II study in early July 2020; FDA granted fast track designation May 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04283461, NCT04405076
BioNTech/ Fosun Pharma/ Pfizer
3 LNP-mRNAs; BNT162
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III trial may start as early as July 2020 (not participating in the NIH testing program); Phase I/II started April 2020; first data released July 1, 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
EudraCT 2020-001038-36, NCT04368728
CureVac
RNA; mRNA
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI); European Commission; Gates Foundation; Defense Advanced Research Projects Agency (DARPA); German Government; European Investment Bank (EIB)
Related use
Related use
n/a
Same platform as vaccine candidates for RABV, LASV, YFV, MERS, InfA, ZIKV, DengV, NIPV
Anticipated Next Steps
Anticipated Next Steps
n/a
Start Phase I/IIa trial June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04449276
Imperial College London/ VacEquity Global Health
RNA; LNP-nCoVsaRNA
Funder
Funder
n/a
UK Government
Related use
Related use
n/a
Same platform as vaccine candidates for EBOV, LASV, MARV, Inf (H7N9), RABV
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I/II trial started June 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ISRCTN17072692
People's Liberation Army (PLA) Academy of Military Sciences/ Walvax Biotech
mRNA
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ChiCTR2000034112
Selcuk University
mRNA
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Chula Vaccine Research Center/University of Pennsylvania
LNP-mRNA
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Chimeron Bio/ George Mason University's National Center for Biodefense and Infectious Disease
Self amplifying RNA, self-assembling delivery system
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Arcturus/Duke-NUS/ Catalent
LUNAR-COV19; RNA; mRNA
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for multiple candidates
Anticipated Next Steps
Anticipated Next Steps
n/a
Start Phase I trial August 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Ziphius Therapeutics/ Ghent University
RNA; ZIP-1642, vaccine consists of a combination of mRNA molecules, encoding multiple SARS-CoV-2 antigens
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Tokyo / Daiichi-Sankyo
RNA; LNP-encapsulated mRNA
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
RNAimmune, Inc.
RNA; several mRNA candidates
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Max Planck Institute of Colloids and Interfaces
mRNA in targeted LPNs (Langerhans cell specific)
Funder
Funder
n/a
KHAN-1 Technology Transfer Fund I GmbH & Co KG
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
GeneOne Life Science / Houston Methodist
RNA
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Greenlight Biosciences
mRNA
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Fudan University / Shanghai JiaoTong University / RNACure Biopharma
RNA; LNP-encapsulated mRNA cocktail encoding RBD
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IDIBAPS- Hospital Clinic, Spain
mRNA
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Fudan University / Shanghai JiaoTong University / RNACure Biopharma
RNA; LNP-encapsulated mRNA cocktail encoding VLP
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
China CDC / Tongji University / Stermina
RNA; mRNA
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
RNA; mRNA
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Centro Nacional Biotecnologia (CNB-CSIC), Spain
RNA; Replicating defective SARS-CoV-2 derived RNAs
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
CanSino Biologics/Precision Nanosystems
RNA; mRNA lipid nanoparticle (mRNA-LNP)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Sanofi Pasteur / Translate Bio
LNP-mRNA
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start Q4 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
eTheRNA Immunotherapies / EpiVax/ Nexelis/ REPROCELL / Centre for the Evaluation of Vaccination of the University of Antwerp
RNA; mRNA in an intranasal delivery system (cross-strain protective COV-2 mRNA) vaccine for high-risk populations
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Start Phase I early 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
BIOCAD
RNA; liposome-encapsulated mRNA
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for cancer
Anticipated Next Steps
Anticipated Next Steps
n/a
Animal studies begin in April 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PRE
I
II
III
RR
IV
Replicating viral vector
This involves putting a gene for a viral protein into a different virus (one that will not cause illness but can replicate). Replication of the viral vector also produces copies of the viral protein, which triggers an immune response to that protein. Examples include ebola and dengue vaccines.
Zydus Cadila Healthcare Limited
Replicating viral vector; measles vector
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
DZIF - German Center for Infection Research/ CanVirex AG
Measles virus (S, N targets)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for Zika, H7N9, CHIKV
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Israel Institute for Biological Research/ Weizmann Institute of Science
VSV-S
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
The University of Hong Kong
Replicating viral vector, influenza vector expressing RBD
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)
Related use
Related use
n/a
Same platform as vaccine candidates for MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
The Lancaster University, UK
Avian paramyxovirus vector (APMV)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Western Ontario
Replicating viral vector; VSV-S
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for HIV, MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Tonix Pharma / Southern Research
Replicating viral vector; horsepox vector expressing S protein; TNX-1800
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for smallpox, monkeypox
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
KU Leuven
Replicating viral vector; YF17D Vector
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.
Newcastle disease virus vector (NDV-SARS-CoV-2/Spike)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
Replicating viral vector; measles vector
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Fundacao Oswaldo Cruz and Instituto Buntantan
Attenuated Influenza expressing an antigenic portion of the Spike protein
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
Replicating viral vector; VSV vector
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
BIOCAD / IEM
Replicating viral vector, live viral vectored vaccine based on attenuated influenza virus backbone (intranasal)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo
Replicating viral vector, recombinant vaccine based on Influenza A virus, for the prevention of COVID-19 (intranasal)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Wisconsin-Madison / FluGen/ Bharat Biotech
M2-deficient single replication (M2SR) influenza vector
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Start Phase I trial in fall 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IAVI/ Merck
Replicating viral vector, replication-competent VSV chimeric virus technology (VSVdeltaG) delivering the SARS-CoV-2 Spike (S) glycoprotein
Funder
Funder
n/a
Biomedical Advanced Research and Development Authority (BARDA)
Related use
Related use
n/a
Same platform as vaccine candidates for Ebola, Marburg, Lassa (including FDA-licensed Ebola vaccine, ERVEBO®)
Anticipated Next Steps
Anticipated Next Steps
n/a
Will join US Operation Warp Speed vaccine trials; clinical studies to start in 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Institut Pasteur / Themis / University of Pittsburgh / Merck
Replicating viral vector; measles vector
Funder
Funder
n/a
Coalition for Epidemic Preparedness (CEPI)
Related use
Related use
n/a
Same platform as vaccine candidates for West nile, CHIKV, Ebola, Lassa, Zika, MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Start animal testing in April 2020; clinical testing to start later in 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PRE
I
II
III
RR
IV
Non-replicating viral vector
This approach is similar to replicating viral vector vaccines in that a viral gene is added to a different, non-replicating, virus and delivered to the vaccine recipient. No approved product of this kind has resulted to date.
Consortium of the Jenner Institute, Oxford Biomedica, University of Oxford, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA, the Serum Institute, Vaccitech, and AstraZeneca
Non-replicating viral vector; AZD 1222 (formerly ChAdOx1)
Funder
Funder
n/a
Coalition for Epidemic Preparedness Innovations (CEPI)/ UK Government/ Biomedical Advanced Research and Development Authority (BARDA)/ Gavi, the Vaccine Alliance
Related use
Related use
n/a
Same platform as vaccine candidates for influenza, TB, Chikungunya, Zika, MenB, plague
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase III enrolling in Brazil end of June 2020; South African trial starts end of June 2020; Will join US Operation Warp Speed Phase III vaccine trials in August 2020; Phase II/III trials enrolling May 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ISRCTN89951424, NCT04324606, EudraCT 2020-001072-15, EudraCT 2020-001228-32, NCT04400838, ISRCTN89951424, PACTR202006922165132
CanSino Biologics/Beijing Institute of Biotechnology/ Canada's National Research Council
Non-replicating viral vector; Adenovirus Type 5 vector (Ad5-nCoV)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for EBOV
Anticipated Next Steps
Anticipated Next Steps
n/a
Approved for military use in China on June 25, 2020; Phase II started April 2020; initial results released May 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04313127 ChiCTR2000030906 ChiCTR2000031781 NCT04398147
Gamaleya Research Institute
Adeno-based
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04437875
Ankara University
Adenovirus-based
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ID Pharma
Sendai virus vector
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
DZIF - German Center for Infection Research/ IDT Biologika GmbH
Non-replicating viral vector; MVA-S encoded
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for many pathogens
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Janssen Pharmaceutical Companies/ Beth Israel Deaconess Medical Center/ Emergent BioSolutions/ Catalent
Ad26.COV2-S, Non replicating viral vector; Ad26 (alone or with MVA boost)
Funder
Funder
n/a
Biomedical Advanced Research and Development Authority (BARDA)
Related use
Related use
n/a
Same platform as vaccine candidates for Ebola, HIV, RSV
Anticipated Next Steps
Anticipated Next Steps
n/a
Will join US Operation Warp Speed vaccine trials in September 2020; Start Phase I/IIa July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
National Research Centre, Egypt
Influenza A H1N1 vector
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ImmunityBio/ NantKwest
Non-replicating viral vector; [E1-, E2b-, E3-] hAd5-COVID19-Spike/Nucleocapsid
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for flu, Chik, Zika, EBOV, LASV, HIV/SIV, cancer
Anticipated Next Steps
Anticipated Next Steps
n/a
Start Phase I in June 2020; vaccine to be included in US Operation Warp Speed trials according to company
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Valo Therapeutics Ltd
Adenovirus-based + HLA-matched peptides (Pan-Corona)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Manitoba
Non-replicating viral vector; dendritic cell-based vaccine
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Georgia/ University of Iowa
Non-replicating viral vector; parainfluenza virus 5 (PIV5)-based vaccine expressing the spike protein
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Stabilitech Biopharma Ltd
Oral Ad5 S
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
National Center for Genetic Engineering and Biotechnology (BIOTEC)/ GPO, Thailand
Inactivated Flu-based SARS-CoV2 vaccine + Adjuvant
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IDIBAPS- Hospital Clinic, Spain
MVA-S
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
GeoVax / BravoVax
Non-replicating viral vector; MVA encoded VLP
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for LASV, EBOV, MARV, HIV
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Greffex
Non-replicating viral vector; Ad5 S (GREVAX™ platform)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for MERS
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Centro Nacional Biotecnologia (CNB-CSIC), Spain
Non-replicating viral vector, MVA expressing structural proteins
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for HIV, HCV, CHIKV, EBOV, Zika, Malaria, Leishmania
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Bharat Biotech/ Thomas Jefferson University
Recombinant deactivated rabies virus containing S1
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Vaxart / Emergent BioSolutions
Non-replicating viral vector; Oral Vaccine platform
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for InfA, CHIKV, LASV, NORV, EBOV, RVF, HBV, VEE
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I trial to begin in the second half of 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ReiThera/ Leukocare/ Univercells
Non-replicating viral vector; replication defective simian adenovirus (GRAd) encoding SARS-CoV-2 S
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Start Phase I in summer 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Grousbeck Gene Therapy Center at Mass. Eye and Ear/ AveXis, a Novartis Company/ Viralgen/ Aldevron/ Catalent/ Penn Medicine
AAVCOVID, Adeno-associated viral vector (AAV), spike protein
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase 1 to begin second half of 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Altimmune / University of Alabama at Birmingham
AdCOVID; single-dose, intranasal vaccine; non replicating viral vector; adenovirus-based NasoVAX expressing spike protein
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for influenza
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I trial to begin Q3 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PRE
I
II
III
RR
IV
Virus-like particle
Virus-like particle (VLP) vaccines closely resemble viruses but are non-infectious because they contain no viral genetic material. Since VLPs cannot replicate, they provide a safer alternative to attenuated viruses. Examples include the HPV vaccine.
Medicago Inc./ GSK
VLP (CoVLP)+ Adjuvant
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Medicago Inc./ Dynavax
VLP (CoVLP)+ Adjuvant (CpG 1018)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start mid-July 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Medicago Inc./ Université Laval
VLP; plant-derived VLP
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for flu, rotavirus, norovirus, West Nile virus, and cancer
Anticipated Next Steps
Anticipated Next Steps
n/a
Start Phase I in July/August 2020; Phase II by the end of 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04450004
Middle East Technical University
VLP
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
OSIVAX
VLP (COVID-19 and SARS1)
Funder
Funder
n/a
European Innovation Council (EIC)
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Doherty Institute
VLP; unknown
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
VBI Vaccines / National Research Council of Canada
Enveloped virus-like particle (eVLP): Pan-coronavirus vaccine candidate, targeting COVID-19, SARS, and MERS, spike protein
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for glioblastoma, cytomegalovirus, and Zika
Anticipated Next Steps
Anticipated Next Steps
n/a
Start Phase I testing by end of 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Mahidol University/ The Government Pharmaceutical Organization (GPO)/ Siriraj Hospital
VLP + Adjuvant
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
IrsiCaixa AIDS Research/ IRTA-CReSA/ Barcelona Supercomputing Centre/ Grifols
S protein integrated in HIV VLPs
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
University of Sao Paulo
VLPs peptides/whole virus
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Saiba GmbH
VLP; virus-like particle, based on RBD displayed on virus-like particle
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Navarrabiomed, Oncoimmunology group
Virus-like particles, lentivirus, and baculovirus vehicles
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ARTES Biotechnology
VLP; eVLP
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Same platform as vaccine candidates for malaria
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Imophoron Ltd / Bristol University's Max Planck Centre
VLP; ADDomerTM multiepitope display
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PRE
I
II
III
RR
IV
Other Vaccines
From a gene-encoded antibody vaccine to a self-assembling vaccine and more, these are the vaccines being developed that do not fall easily into one of the other product categories or details about its category are not publicly available.
Adeleke University
Unknown
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NidoVax
unknown; IMT504 technology
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Vault Pharma/ University of California Los Angeles
nanoparticles (vaults) as second-line defense of infection
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Vivaldi Biosciences/ Esco Aster Pte Ltd
Chimeric vaccine (coronavirus and influenza)
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Universite Laval
Unknown
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Vir Biotechnology / GSK
Unknown
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Tulane University
Unknown
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
SmartPharm Therapeutics / Sorrento Therapeutics
Gene-encoded antibody vaccine, non-viral nanoparticle delivery
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Shenzhen Geno-Immune Medical Institute
LV-SMENP-DC Dendritic cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins; administered with antigen-specific cytotoxic T lymphocytes
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04276896
Shenzhen Geno-Immune Medical Institute
Artificial antigen-presenting cells modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
NCT04299724
Precision Vaccines Program at Boston Children's Hospital
Unknown
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Emergex Vaccines/ George Mason University's National Center for Biodefense and Infectious Diseases (NCBID)
Unknown
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Catholic University/ Millennium Institute of Immunology and Immunotherapy/ Technological Consortium in Clinical Molecular Biomedicine, Chile
Unknown
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Codiak BioSciences/ Ragon Institute
exoVACC exome platform
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
AbVision
AVI-205
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Unknown
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
SK Biosciences
Unknown
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I begins as early as September 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Oragenics (Noachis Terra)/ Aragen Bioscience
TerraCoV2
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Start Phase I in late 2020 or early 2021
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
ISR Immune System Regulation
ISR-50
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Animal study results expected in Q2 2020, Phase I begins Q4 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Covaxx
Unknown
Funder
Funder
n/a
Unknown
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Phase I to start in summer 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
HaloVax (Voltron Therapeutics) / The Vaccine & Immunotherapy Center at the Massachusetts General Hospital
Self-assembling vaccine (fusion protein of a heat shock protein and Avidin, with biotinylated immunogenic peptides)
Funder
Funder
n/a
Analog Devices Foundation
Related use
Related use
n/a
Anticipated Next Steps
Anticipated Next Steps
n/a
Animal study results by October 2020
Clinical Trials for COVID-19
Clinical Trials for COVID-19
n/a
Developer / Researcher
Product Description
PRE
I
II
III
RR
IV
Covid-19 vaccine tracker

Mobile and tablet experiences coming soon